Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 14, 2011

View Archived Issues

Targacept begins phase II trials of TC-6987 in asthma and type 2 diabetes

IntelGenx's INT-0022 shows bioequivalence to a leading antipsychotic

Gilead resubmits NDA for single-tablet Truvada/TMC-278 regimen in HIV-1

Protein S100-A12 levels correlate with pathological activity in Behcet's disease / News in Context

Botulinum neurotoxin type A is efficacious in urological disorders

PF-04605412 displays marked antitumor effects in vivo

Dentin matrix acidic phosphoprotein 1 plays a role in angiogenesis

Mallinckrodt describes new prodrugs of hydromorphone

New deuterated 2,4-pyrimidinediamines claimed for autoimmune diseases

New urotensin UT receptor antagonists divulged

Taisho Pharma patents new inhibitors of GlyT1

Sareum provides update on Aurora+FLT3 kinase program

Promedior begins phase Ib PRM-151 trial in idiopathic pulmonary fibrosis

Theravance identifies novel inhibitors of NET and 5HTT

Neuralstem provides update on stem cell study for ALS

INX-08189 receives FDA fast track status in chronic hepatitis C

Intellikine and PKD Foundation collaborate on treatment of polycystic kidney disease

Genta begins tesetaxel trial in advanced prostate cancer

Candesartan heart failure therapy is associated with lower all-cause mortality than losartan

Alexion acquires investigational therapy for molybdenum cofactor deficiency

Zogenix completes enrollment in phase III efficacy trial of ZX-002

Renovo's phase III REVISE trial of Juvista does not meet primary or secondary endpoints

Medivir and Janssen enter R&D collaboration for dengue virus infection

Eisai and Teikoku Seiyaku enter license agreement for transdermal Aricept in Japan

BioSante to continue enrollment in phase III LibiGel program following safety review

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 8, 2026.
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Infensa Bioscience identifies new ASIC blockers
BioWorld Science
Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...
Kymera’s IRF5 degrader shows potential in IBD treatment
BioWorld Science
At the recently concluded Digestive Disease Week, researchers from Kymera Therapeutics Inc. presented preclinical efficacy data on KT-579, a selective oral IRF5...